Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice

References

• Lupu A, Diculescu M, Diaconescu R, et al. Prevalence of anemia and iron deficiency in Romanian patients with inflammatory bowel disease: a prospective multicenter study. J Gastrointestin Liver Dis. 2015;24:15–20.
   PubMed Web of Science ®Google Scholar
• Ott C, Liebold A, Takses A, et al. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterology Research and Practice. 2012;2012:1.
   Web of Science ®Google Scholar
• Allen RP, Auerbach S, Bahrain H, et al. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. Am J Hematol. 2013;88:261–264.
   PubMed Web of Science ®Google Scholar
• Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010;95:199–205.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299–1307.
   PubMed Web of Science ®Google Scholar
• Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflammatory Bowel Diseases. 2006;12:123–130.
   PubMed Web of Science ®Google Scholar
• Agarwal R. Nonhematological benefits of iron. Am J Nephrol. 2007;27:565–571.
   PubMed Web of Science ®Google Scholar
• Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Diseases. 2006;12:1101–1106.
   PubMed Web of Science ®Google Scholar
• Martinelli M, Strisciuglio C, Alessandrella A, et al. Serum hepcidin and iron absorption in paediatric inflammatory bowel disease. J Crohns Colitis. 2016;10:566–574.
   PubMed Web of Science ®Google Scholar
• Loitsch SM, Diehl D, Hartmann F, et al. Impaired intestinal iron absorption in inflammatory bowel disease correlates with disease activity and markers of inflammation but is independent of disease location. Gastroenterology. 2011;140:S-5–S5.
   Web of Science ®Google Scholar
• Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7:599–610.
   PubMed Web of Science ®Google Scholar
• Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10:e0117383.
   PubMed Web of Science ®Google Scholar
• Stein J, Aksan A, Farrag K, et al. Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. Expert Opin Pharmacother. 2017;18:1721–1737.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95:e2308.
   PubMed Web of Science ®Google Scholar
• Guidance for Industry E9 Statistical Principles for Clinical Trials. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). September 1998 ICH. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073137.pdf.
   Google Scholar
• Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545–1553.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. Crohn’s Colitis. 2013;7:1–33.
   PubMed Web of Science ®Google Scholar
• Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohn’s Colitis. 2015;9:211–222.
   Google Scholar
• Martin J, Radeke HH, Dignass A, et al. Current evaluation and management of anemia in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017;11:19–32.
   PubMed Web of Science ®Google Scholar
• Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78:480–491.
   PubMed Web of Science ®Google Scholar
• Mace TA, Syed A, Bhandari S. Iron (III) isomaltoside 1000. Expert Rev Hematol. 2013;6:239–246.
   PubMed Web of Science ®Google Scholar
• Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;30:1577–1589.
   PubMed Web of Science ®Google Scholar
• Biggar P, Leistikow F, Walper AA. prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia. Cn. 2016;86:310–318.
   Web of Science ®Google Scholar
• Birgegård G, Henry D, Glaspy J, et al. A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: The PROFOUND trial. Pharmacotherapy. 2016;36:402–414.
   PubMed Web of Science ®Google Scholar
• Dahlerup JF, Jacobsen BA, van der Woude J, et al. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016;51:1332–1338.
   PubMed Web of Science ®Google Scholar
• Holm C, Thomsen LL, Norgaard A, et al. Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial. Trials. 2015;16:5.
   PubMed Web of Science ®Google Scholar
• Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang. 2015;109:257–266.
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia. Int J Nephrol Renovascular Dis. 2016;9:53–64.
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31:646–655.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Altorjay I, Zsigmond F, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:1226–1233.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108:1877–1888.
   PubMed Web of Science ®Google Scholar
• Unger EL, Earley CJ, Thomsen LL, et al. Effects of IV iron isomaltoside-1000 treatment on regional brain iron status in an iron-deficient animal. Neuroscience. 2013;246:179–185.
   PubMed Web of Science ®Google Scholar
• Nordfjeld K, Andreasen H, Thomsen LL. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des Devel Ther. 2012;6:43–51.
   PubMed Web of Science ®Google Scholar
• Best WR. Predicting the Crohn’s disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis. 2006;12:304–310.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. The N Engl J Med. 1987;317:1625–1629.
   PubMed Web of Science ®Google Scholar
• Gomollon F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol. 2009;15:4659–4665.
   PubMed Web of Science ®Google Scholar
• Goldberg ND. Iron deficiency anemia in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2013;6:61–70.
   PubMedGoogle Scholar
• Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014;20:936–945.
   PubMed Web of Science ®Google Scholar
• Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther. 2011;5:51–60.
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Anker SD, Ponikowski P, et al. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011;8:485–493.
   PubMed Web of Science ®Google Scholar
• HILDEBRANDT PERR, BRUUN NIELSE, NIELSEN OLAVW, et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A Pilot Study. TATM. 2010;11:131–137.
   Google Scholar
• Dahlerup J, Lindgren S. High dose intravenous iron isomaltoside 1000 in patients with inflammatory bowel disease – the PROMISE trial. Poster presented at 10th Congress of the European Crohn’s and Colitis Organisation (ECCO), 8–21 February 2015, Barcelona, Spain.
   Google Scholar
• Holm C. Iron treatment of fatigue in women after postpartum hemorrhage. WWI FIGO world congress, 4–9 October 2015, Vancouver, Canada.
   Google Scholar
• Frigstad SO, Rannem T, Hellstrom PM, et al. Scandinavian prospective observational study of iron isomaltoside 1000 treatment: Clinical practice and outcomes in iron deficiency anaemia in patients with IBD. Poster presented at 10th Congress of the European Crohn’s and Colitis Organisation (ECCO), 8–21 February 2015, Barcelona, Spain.
   Google Scholar